Hospital Cardio Growth Medicure already markets AGGRASTAT injections, a leading hospital-administered antiplatelet in cardiac catheterization labs. This points to strong relationships with hospital pharmacists, cardiology departments, and interventional labs, suggesting sales opportunities to expandnya within hospital systems, expand product utilization in cath labs, and upsell to peri-procedural areas.

Statin Expansion ZYPITAMAG pitavastatin tablets are FDA-approved since 2017 and targeted for U.S. prescribers. There is potential to broaden market penetration among primary care and cardiology cohorts, and to pursue formulary placements or patient access programs to increase volume and payer coverage.

Post-Acquisition Access The Marley Drug acquisition enhances patient access channels in North Carolina, indicating a successful distribution footprint and direct-to-patient capabilities that could be leveraged to roll out additional products, expand the geographic reach, and improve patient adherence programs.

Leadership & Finance Changes Recent executive transitions including interim CFO appointment and board changes signal the need for clear communication of strategic priorities to finance and procurement teams. This presents an opportunity to align on go-to-market plans, capital investments, and near-term product launches or partnerships.

Clinical & Partnerships Active clinical trial activity and conference involvement, such as MEND-PNPO updates and neurology-focused events, open doors for collaboration with healthcare providers, contract research organizations, and payers to extend the pipeline, co-develop studies, or secure early access for new cardiovascular therapies.